Select your country

13.11.2018
STADA’s €300,000,000 1.75% Senior Notes due 2022: announcement of an instruction to grant in rem securities

STADA’s €300,000,000 1.75% Senior Notes due 2022: announcement of an instruction to grant in rem securities

Read more

18.09.2018
Voting results of the bondholders’ meeting concerning the STADA-Bond 2015/2022

Voting results of the bondholders’ meeting concerning the STADA-Bond 2015/2022

Read more

12.09.2018
STADA invites the holders of the STADA Bond to participate in the bondholders‘ meeting

STADA invites the holders of the STADA Bond to participate in the bondholders‘ meeting

Read more

09.08.2018
STADA’s business development in the first six months of 2018 as expected

STADA’s business development in the first six months of 2018 as expected

Read more

06.08.2018
Strategic portfolio expansion

Strategic portfolio expansion

STADA becomes Majority Shareholder of BIOCEUTICALS Arzneimittel AG

Read more

20.07.2018
STADA Launches Anti-Cancer Drug Pemetrexed

STADA Launches Anti-Cancer Drug Pemetrexed

STADAPHARM GmbH will from now on distribute cytostatic drug Pemetrexed STADA®.

Read more

18.07.2018
STADA Repurchases Rights for Ladival

STADA Repurchases Rights for Ladival

STADA Arzneimittel AG and Ladival GmbH & Co KG have agreed to transfer the rights for the sunscreen Ladival back to the German pharmaceu…

Read more

17.07.2018
STADA: Voting results of the bondholders’ meeting on July 17, 2018 concerning the STADA-Bond 2015/2022: Appointment of One Square Advisory Services GmbH as joint representative and adjournment of the further agenda items

STADA: Voting results of the bondholders’ meeting on July 17, 2018 concerning the STADA-Bond 2015/2022: Appointment of One Square Advisory Services GmbH as joint representative and adjournment of the further agenda items

Read more

12.07.2018
Xbrane and STADA enter into a co-development agreement for Xlucane

Xbrane and STADA enter into a co-development agreement for Xlucane

Xbrane Biopharma AB (“Xbrane”) and STADA Arzneimittel AG (“STADA”) have entered into a co-development agreement for Xlucane, a Lucentis® (ra…

Read more

11.07.2018
STADA Arzneimittel AG: Announcement of the results of the Tender Offer regarding the STADA-Bond 2015/2022

STADA Arzneimittel AG: Announcement of the results of the Tender Offer regarding the STADA-Bond 2015/2022

Read more

29.06.2018
NOT FOR DISTRIBUTION TO ANY U.S. PERSON OR IN OR INTO OR TO ANY PERSON LOCATED IN THE UNITED STATES.

NOT FOR DISTRIBUTION TO ANY U.S. PERSON OR IN OR INTO OR TO ANY PERSON LOCATED IN THE UNITED STATES.

Read more

15.06.2018
STADA recovers top-selling product and will distribute the Parkinson's medication in Germany and Scandinavia in the future

STADA recovers top-selling product and will distribute the Parkinson's medication in Germany and Scandinavia in the future

STADA continues to advance its strategic reorientation.

Read more

08.06.2018
STADA Arzneimittel AG: Consent Solicitation for STADA Euro bond 2015/2022

STADA Arzneimittel AG: Consent Solicitation for STADA Euro bond 2015/2022

STADA has today published the solicitation to the noteholders of the STADA Euro bond 2015/2022.

Read more

06.06.2018
STADA: Annual General Meeting approves agenda items with a large majority

STADA: Annual General Meeting approves agenda items with a large majority

STADA Arzneimittel AG announced today that the Company’s shareholders approved all agenda items with a large majority that were put to a vot…

Read more

03.05.2018
STADA with solid business development in the first quarter of 2018

STADA with solid business development in the first quarter of 2018

Read more

16.04.2018
Changes in the management team of STADA

Changes in the management team of STADA

STADA is systematically pushing ahead with the new strategy announced in March.

Read more

23.03.2018
STADA: Executive Board of STADA Arzneimittel AG decides to file application related to change of sub-segment of the stock exchange

STADA: Executive Board of STADA Arzneimittel AG decides to file application related to change of sub-segment of the stock exchange

STADA: Executive Board of STADA Arzneimittel AG decides to file application related to change of sub-segment of the stock exchange

Read more

20.03.2018
STADA: Domination and profit and loss transfer agreement between STADA Arzneimittel AG and Nidda Healthcare GmbH takes effect / beginning of acceptance period for severance offer

STADA: Domination and profit and loss transfer agreement between STADA Arzneimittel AG and Nidda Healthcare GmbH takes effect / beginning of acceptance period for severance offer

STADA: Domination and profit and loss transfer agreement between STADA Arzneimittel AG and Nidda Healthcare GmbH takes effect / beginning of…

Read more

08.03.2018
CEO Albrecht to modernize STADA – Biosimilars to focus on oncology, CNS, diabetes and ophthalmology

CEO Albrecht to modernize STADA – Biosimilars to focus on oncology, CNS, diabetes and ophthalmology

CEO Albrecht to modernize STADA – Biosimilars to focus on oncology, CNS, diabetes and ophthalmology

Read more

08.03.2018
More focused and aggressive

More focused and aggressive

At the press conference on March 8, 2018 STADA CEO Dr. Claudio Albrecht presented his vision for STADA and the company’s new strategy. In th…

Read more

08.03.2018
STADA: Executive Board and Supervisory Board of STADA Arzneimittel AG resolve on a proposal for the appropriation of profits and propose a dividend in the amount of €0.11 per share

STADA: Executive Board and Supervisory Board of STADA Arzneimittel AG resolve on a proposal for the appropriation of profits and propose a dividend in the amount of €0.11 per share

STADA: Executive Board and Supervisory Board of STADA Arzneimittel AG resolve on a proposal for the appropriation of profits and propose a d…

Read more

02.02.2018
STADA: General Meeting approves domination and profit and loss transfer agreement with Nidda Healthcare GmbH

STADA: General Meeting approves domination and profit and loss transfer agreement with Nidda Healthcare GmbH

The Extraordinary General Meeting of STADA Arzneimittel AG (STADA) on February 2, 2018 with a majority of 99 percent approved the conclusion…

Read more

02.02.2018
STADA: General Meeting approves domination and profit and loss transfer agreement with Nidda Healthcare GmbH

STADA: General Meeting approves domination and profit and loss transfer agreement with Nidda Healthcare GmbH

Read more

01.02.2018
STADA set for continuity: Peter Goldschmidt to succeed Claudio Albrecht as CEO on 1 September 2018

STADA set for continuity: Peter Goldschmidt to succeed Claudio Albrecht as CEO on 1 September 2018

Read more

01.02.2018
STADA Arzneimittel AG: Supervisory Board of STADA Arzneimittel AG appoints Peter Goldschmidt as new Chairman of the Executive Board as of September 1, 2018

STADA Arzneimittel AG: Supervisory Board of STADA Arzneimittel AG appoints Peter Goldschmidt as new Chairman of the Executive Board as of September 1, 2018

The Supervisory Board of STADA Arzneimittel AG appointed Peter Goldschmidt today as new Chairman of the Executive Board as of September 1, 2…

Read more

18.01.2018
Internationalization of OTC brands: STADA agrees to early termination of license agreement with Sanofi for head lice lotion Hedrin

Internationalization of OTC brands: STADA agrees to early termination of license agreement with Sanofi for head lice lotion Hedrin

STADA is advancing the internationalization of its OTC brand business.

Read more

19.12.2017
STADA: domination and profit and loss transfer agreement pursuant to sections 291 et seqq. AktG concluded between STADA Arzneimittel AG and Nidda Healthcare GmbH

STADA: domination and profit and loss transfer agreement pursuant to sections 291 et seqq. AktG concluded between STADA Arzneimittel AG and Nidda Healthcare GmbH

STADA: domination and profit and loss transfer agreement pursuant to sections 291 et seqq. AktG concluded between STADA Arzneimittel AG and …

Read more

17.10.2017
Frank Staud assumes overall responsibility for the STADA brand and communications

Frank Staud assumes overall responsibility for the STADA brand and communications

Frank Staud assumes overall responsibility for the STADA brand and communications

Read more

28.09.2017
Dr. Claudio Albrecht appointed CEO and Mark Keatley CFO of STADA Arzneimittel AG

Dr. Claudio Albrecht appointed CEO and Mark Keatley CFO of STADA Arzneimittel AG

Dr. Claudio Albrecht appointed CEO and Mark Keatley CFO of STADA Arzneimittel AG

Read more

27.09.2017
Supervisory Board of STADA Arzneimittel AG elects Dr. Günter von Au as new Chairman

Supervisory Board of STADA Arzneimittel AG elects Dr. Günter von Au as new Chairman

Supervisory Board of STADA Arzneimittel AG elects Dr. Günter von Au as new Chairman

Read more

30.08.2017
STADA Annual General Meeting: Approval of the actions of the Executive Board for financial year 2016 postponed – guidance 2017 confirmed

STADA Annual General Meeting: Approval of the actions of the Executive Board for financial year 2016 postponed – guidance 2017 confirmed

STADA Annual General Meeting: Approval of the actions of the Executive Board for financial year 2016 postponed – guidance 2017 confirmed

Read more

25.08.2017
Following the successful takeover vote for STADA: Members of the Supervisory Board to step down from their posts

Following the successful takeover vote for STADA: Members of the Supervisory Board to step down from their posts

Following the successful takeover vote for STADA: Members of the Supervisory Board to step down from their posts

Read more

25.08.2017
Changes on the Supervisory Board of STADA Arzneimittel AG due to the takeover by Bain Capital and Cinven

Changes on the Supervisory Board of STADA Arzneimittel AG due to the takeover by Bain Capital and Cinven

Changes on the Supervisory Board of STADA Arzneimittel AG due to the takeover by Bain Capital and Cinven

Read more

25.08.2017
Following the successful takeover vote for STADA: Members of the Supervisory Board to step down from their posts

Following the successful takeover vote for STADA: Members of the Supervisory Board to step down from their posts

Following the successful takeover vote for STADA: Members of the Supervisory Board to step down from their posts

Read more

24.08.2017
Entering into negotiations of a domination and profit and loss pooling agreement between STADA Arzneimittel AG and Nidda Healthcare Holding AG

Entering into negotiations of a domination and profit and loss pooling agreement between STADA Arzneimittel AG and Nidda Healthcare Holding AG

Entering into negotiations of a domination and profit and loss pooling agreement between STADA Arzneimittel AG and Nidda Healthcare Holding …

Read more

18.08.2017
STADA takeover offer by Bain Capital and Cinven successful

STADA takeover offer by Bain Capital and Cinven successful

STADA takeover offer by Bain Capital and Cinven successful

Read more

18.08.2017
Minimum acceptance threshold for STADA takeover by Bain Capital and Cinven reached

Minimum acceptance threshold for STADA takeover by Bain Capital and Cinven reached

Minimum acceptance threshold for STADA takeover by Bain Capital and Cinven reached

Read more

03.08.2017
STADA shows good operational development in first six months of 2017

STADA shows good operational development in first six months of 2017

STADA shows good operational development in first six months of 2017

Read more

25.07.2017
Executive Board and Supervisory Board of STADA recommend acceptance of the renewed takeover offer by Bain Capital and Cinven

Executive Board and Supervisory Board of STADA recommend acceptance of the renewed takeover offer by Bain Capital and Cinven

Executive Board and Supervisory Board of STADA recommend acceptance of the renewed takeover offer by Bain Capital and Cinven

Read more

19.07.2017
Bain Capital and Cinven publish offer document on the renewed voluntary public takeover offer for STADA Arzneimittel AG

Bain Capital and Cinven publish offer document on the renewed voluntary public takeover offer for STADA Arzneimittel AG

Bain Capital and Cinven publish offer document on the renewed voluntary public takeover offer for STADA Arzneimittel AG

Read more

10.07.2017
STADA supports renewed improved takeover offer announced by Bain Capital and Cinven

STADA supports renewed improved takeover offer announced by Bain Capital and Cinven

STADA supports renewed improved takeover offer announced by Bain Capital and Cinven

Read more

10.07.2017
Bain Capital and Cinven applied for an exemption from one-year exclusion period for the submission of a renewed voluntary public takeover offer with STADA’s consent

Bain Capital and Cinven applied for an exemption from one-year exclusion period for the submission of a renewed voluntary public takeover offer with STADA’s consent

Bain Capital and Cinven applied for an exemption from one-year exclusion period for the submission of a renewed voluntary public takeover of…

Read more

04.07.2017
STADA Arzneimittel AG appoints new Chief Executive Officer and Chief Financial Officer – incumbents step down from their positions

STADA Arzneimittel AG appoints new Chief Executive Officer and Chief Financial Officer – incumbents step down from their positions

STADA Arzneimittel AG appoints new Chief Executive Officer and Chief Financial Officer – incumbents step down from their positions

Read more

04.07.2017
Changes in the Executive Board of STADA Arzneimittel AG

Changes in the Executive Board of STADA Arzneimittel AG

Changes in the Executive Board of STADA Arzneimittel AG

Read more

04.07.2017
STADA Arzneimittel AG confirms that Bain Capital and Cinven are considering to apply for an exemption from one-year exclusion period for the submission of a renewed voluntary public takeover offer

STADA Arzneimittel AG confirms that Bain Capital and Cinven are considering to apply for an exemption from one-year exclusion period for the submission of a renewed voluntary public takeover offer

STADA Arzneimittel AG confirms that Bain Capital and Cinven are considering to apply for an exemption from one-year exclusion period for the…

Read more

26.06.2017
STADA Arzneimittel AG: Voluntary public takeover offer by Bain Capital and Cinven not successful

STADA Arzneimittel AG: Voluntary public takeover offer by Bain Capital and Cinven not successful

STADA Arzneimittel AG: Voluntary public takeover offer by Bain Capital and Cinven not successful

Read more

07.06.2017
STADA: Bain Capital and Cinven lower the minimum acceptance threshold for the takeover offer to STADA’s shareholders from 75 percent to 67.5 percent – acceptance period extended until June 22, 2017

STADA: Bain Capital and Cinven lower the minimum acceptance threshold for the takeover offer to STADA’s shareholders from 75 percent to 67.5 percent – acceptance period extended until June 22, 2017

STADA: Bain Capital and Cinven lower the minimum acceptance threshold for the takeover offer to STADA’s shareholders from 75 percent to 67.5…

Read more

11.05.2017
STADA: Executive Board and Supervisory Board of STADA Arzneimittel AG recommend acceptance of the voluntary public takeover offer by Bain Capital and Cinven

STADA: Executive Board and Supervisory Board of STADA Arzneimittel AG recommend acceptance of the voluntary public takeover offer by Bain Capital and Cinven

STADA: Executive Board and Supervisory Board of STADA Arzneimittel AG recommend acceptance of the voluntary public takeover offer by Bain Ca…

Read more

11.05.2017
STADA: Very good start in first quarter 2017

STADA: Very good start in first quarter 2017

STADA: Very good start in first quarter 2017

Read more

27.04.2017
STADA: Publication of the offer document on the voluntary public tender for STADA Arzneimittel AG by Bain Capital and Cinven

STADA: Publication of the offer document on the voluntary public tender for STADA Arzneimittel AG by Bain Capital and Cinven

STADA: Publication of the offer document on the voluntary public tender for STADA Arzneimittel AG by Bain Capital and Cinven

Read more

10.04.2017
To the shareholders of STADA Arzneimittel AG: STADA supports voluntary public tender offer by Bain Capital and Cinven

To the shareholders of STADA Arzneimittel AG: STADA supports voluntary public tender offer by Bain Capital and Cinven

To the shareholders of STADA Arzneimittel AG: STADA supports voluntary public tender offer by Bain Capital and Cinven

Read more

10.04.2017
STADA supports the voluntary public tender offer by Bain Capital and Cinven worth Euro 66.00 per share

STADA supports the voluntary public tender offer by Bain Capital and Cinven worth Euro 66.00 per share

STADA supports the voluntary public tender offer by Bain Capital and Cinven worth Euro 66.00 per share

Read more

29.03.2017
STADA: Final figures for 2016 confirm good year-end results – medium term growth targets for 2019 raised

STADA: Final figures for 2016 confirm good year-end results – medium term growth targets for 2019 raised

STADA: Final figures for 2016 confirm good year-end results – medium term growth targets for 2019 raised

Read more

21.03.2017
STADA postpones press and analyst conference on full year figures 2016  to March 29, 2017

STADA postpones press and analyst conference on full year figures 2016 to March 29, 2017

STADA postpones press and analyst conference on full year figures 2016
to March 29, 2017

Read more

17.03.2017
STADA leverages positive momentum and raises targets for future-oriented program “STADA Plus”

STADA leverages positive momentum and raises targets for future-oriented program “STADA Plus”

STADA leverages positive momentum and raises targets for future-oriented program “STADA Plus”

Read more

17.03.2017
STADA raises medium-term growth targets

STADA raises medium-term growth targets

STADA raises medium-term growth targets

Read more

16.03.2017
STADA: Statement on media reports

STADA: Statement on media reports

STADA: Statement on media reports

Read more

01.03.2017
STADA: Earnings 2016 slightly above expectations – Growth to continue in 2017

STADA: Earnings 2016 slightly above expectations – Growth to continue in 2017

STADA: Earnings 2016 slightly above expectations – Growth to continue in 2017

Read more

25.02.2017
STADA conducts structured and open bidding process with all interested parties

STADA conducts structured and open bidding process with all interested parties

Read more

23.02.2017
STADA Arzneimittel AG informs about receipt of binding, conditional take-over offer

STADA Arzneimittel AG informs about receipt of binding, conditional take-over offer

Read more

16.02.2017
STADA Arzneimittel AG confirms receipt of another non-binding expression of interest in takeover bid

STADA Arzneimittel AG confirms receipt of another non-binding expression of interest in takeover bid

STADA Arzneimittel AG confirms receipt of another non-binding expression of interest in takeover bid

Read more

12.02.2017
STADA Arzneimittel AG confirms receipt of non-binding expressions of interest in takeover bid

STADA Arzneimittel AG confirms receipt of non-binding expressions of interest in takeover bid

STADA Arzneimittel AG confirms receipt of non-binding expressions of interest in takeover bid

Read more

23.01.2017
Changes in the Executive Board of STADA Arzneimittel AG

Changes in the Executive Board of STADA Arzneimittel AG

Changes in the Executive Board of STADA Arzneimittel AG

Read more

21.11.2016
STADA acquires UK branded product company Natures Aid

STADA acquires UK branded product company Natures Aid

STADA acquires UK branded product company Natures Aid

Read more

10.11.2016
STADA records further growth in the first nine months of 2016 – Adjusted net income of at least Euro 180 million now expected for full year 2016

STADA records further growth in the first nine months of 2016 – Adjusted net income of at least Euro 180 million now expected for full year 2016

STADA records further growth in the first nine months of 2016 – Adjusted net income of at least Euro 180 million now expected for full year …

Read more

05.10.2016
STADA lays the groundwork for sustainable growth

STADA lays the groundwork for sustainable growth

STADA lays the groundwork for sustainable growth

Read more

05.09.2016
Leslie Iltgen is the new Vice President Investor Relations

Leslie Iltgen is the new Vice President Investor Relations

STADA: Leslie Iltgen is the new Vice President Investor Relations

Read more

26.08.2016
STADA: Shareholder Meeting resolves to remove supervisory board chairman Dr. Martin Abend from the supervisory board

STADA: Shareholder Meeting resolves to remove supervisory board chairman Dr. Martin Abend from the supervisory board

STADA: Shareholder Meeting resolves to remove supervisory board chairman Dr. Martin Abend from the supervisory board

Read more

04.08.2016
STADA: Excellent business development in the first six months of 2016

STADA: Excellent business development in the first six months of 2016

STADA: Excellent business development in the first six months of 2016 – reported and adjusted key earnings figures significantly above previ…

Read more

11.07.2016
STADA approves growth targets for 2019

STADA approves growth targets for 2019

STADA approves growth targets for 2019: adjusted Group sales Euro 2.6 billion, adjusted EBITDA Euro 510 million and adjusted net income Euro…

Read more

23.03.2016
STADA: Development in 2015 as expected under difficult framework conditions – dividend to increase – outlook for 2016 confirmed

STADA: Development in 2015 as expected under difficult framework conditions – dividend to increase – outlook for 2016 confirmed

STADA: Development in 2015 as expected under difficult framework conditions – dividend to increase – outlook for 2016 confirmed

Read more

29.02.2016
STADA: Development as expected in 2015 under difficult framework conditions – dividend to increase – preliminary outlook for 2016 published

STADA: Development as expected in 2015 under difficult framework conditions – dividend to increase – preliminary outlook for 2016 published

STADA: Development as expected in 2015 under difficult framework conditions – dividend to increase – preliminary outlook for 2016 published

Read more

01.04.2015
STADA: Successful refinancing at favorable conditions through the placement of a further corporate bond in the total amount of Euro 300 million

STADA: Successful refinancing at favorable conditions through the placement of a further corporate bond in the total amount of Euro 300 million

STADA: Successful refinancing at favorable conditions through the placement of a further corporate bond in the total amount of Euro 300 mill…

Read more

08.08.2013
STADA with dynamic sales growth in the first half of 2013

STADA with dynamic sales growth in the first half of 2013

STADA with dynamic sales growth in the first half of 2013

Read more

05.06.2013
STADA: Executive Board gives a positive summary of 2012 at Annual General Meeting and adheres to the positive outlook till 2014 – Supervisory Board members approved

STADA: Executive Board gives a positive summary of 2012 at Annual General Meeting and adheres to the positive outlook till 2014 – Supervisory Board members approved

STADA: Executive Board gives a positive summary of 2012 at Annual General Meeting and adheres to the positive outlook till 2014 – Supervisor…

Read more

29.05.2013
STADA: Successful placement of a corporate bond in the amount of Euro 350 million

STADA: Successful placement of a corporate bond in the amount of Euro 350 million

STADA: Successful placement of a corporate bond in the amount of Euro 350 million

Read more

07.05.2013
STADA: Good start in the first quarter of 2013 – organic growth accelerated

STADA: Good start in the first quarter of 2013 – organic growth accelerated

STADA: Good start in the first quarter of 2013 – organic growth accelerated

Read more

16.04.2013
With "STADA Diagnostik" STADA is entering the personalized drug therapy business

With "STADA Diagnostik" STADA is entering the personalized drug therapy business

With "STADA Diagnostik" STADA is entering the personalized drug therapy business

Read more

21.03.2013
STADA to establish logistics and distribution center in Dubai

STADA to establish logistics and distribution center in Dubai

STADA to establish logistics and distribution center in Dubai

Read more

21.03.2013
STADA: Successful financial year 2012 – Adjusted EBITDA at record level – Dividend to increase by over 35 percent – Positive outlook to 2014

STADA: Successful financial year 2012 – Adjusted EBITDA at record level – Dividend to increase by over 35 percent – Positive outlook to 2014

STADA: Successful financial year 2012 – Adjusted EBITDA at record level – Dividend to increase by over 35 percent – Positive outlook to 2014…

Read more

28.02.2013
STADA: Preliminary figures 2012 demonstrate successful financial year – dividend to increase by more than 35 percent

STADA: Preliminary figures 2012 demonstrate successful financial year – dividend to increase by more than 35 percent

Read more

05.02.2013
AOK 11 tender round: STADA takes top active ingredients

AOK 11 tender round: STADA takes top active ingredients

AOK 11 tender round: STADA takes top active ingredients

Read more

31.01.2013
STADA's subsidiary Eurogenerics increases profitability with new distribution agreement in Belgium

STADA's subsidiary Eurogenerics increases profitability with new distribution agreement in Belgium

STADA's subsidiary Eurogenerics increases profitability with new distribution agreement in Belgium

Read more

25.01.2013
STADA wins discount agreement tenders with Germany’s three largest public health insurers

STADA wins discount agreement tenders with Germany’s three largest public health insurers

STADA wins discount agreement tenders with Germany’s three largest public health insurers

Read more

23.01.2013
STADA scholarships support the advancement of Charité top performers

STADA scholarships support the advancement of Charité top performers

STADA scholarships support the advancement of Charité top performers

Read more